Introduction ▼
The use of anticholinergic drugs (ACM) in the treatment of drug-induced extrapyramidal side eff ects (EPS) has been a controversial issue, particularly their continuous prescription in chronic schizophrenia [1 -3] . Side eff ects related to ACM are cognitive impairment [4, 5] , the potential for abuse [6] , central anticholinergic syndrome at higher doses [7] , worsening of positive symptoms [8] , and elevated risk for tardive dyskinesia (TD) [9] . Nevertheless, ACM can improve patients ' treatment adherence [2, 10] and have no euphoriant eff ects at therapeutic doses [11] . Preliminary evidence suggests that Asian patients require lower doses of antipsychotics and that they are more sensitive to EPS compared with their Western counterparts [12, 13] . Repeated surveys in the same region are more useful than a single survey because longitudinal studies can reveal important trends in pharmacotherapy over time and help to evaluate the eff ectiveness of education and training of clinicians. Sim et al. [14] found that 34.7 -82 % of 2 399 schizophrenia inpatients in 6 Asian countries and territories in which is an ongoing pharmaco-epidemiological survey designed to refl ect the prescription trends of psychotropic drugs in hospitalized schizophrenia patients in 6 Asian countries and territories, including mainland China (in the following: China), Hong Kong, Taiwan, Singapore, Japan, and Korea using a standardized protocol and data collection procedure. Centers in India, Malaysia, and Thailand joined the survey in 2009. The 3 REAP surveys were conducted in July 2001, July 2004, and October 2008 -March 2009. Details of the REAP project methodology have been described elsewhere [15, 16] . Participating patients needed to satisfy the following study criteria: (i) ICD-10 or DSM-IV schizophrenia; (ii) be able to comprehend the aims of the study; and (iii) be willing to provide written or oral consent according to the requirements of the clinical research ethics committees in the respective study sites. Patients suff ering from major medical conditions were excluded. The study was approved by the Institutional Review Boards of the respective centers. Eligible patients were recruited consecutively, and their sociodemographic and clinical variables including age, sex, the type and dose of antipsychotics, signifi cant symptoms (both positive and negative) within the past month, and extrapyramidal side eff ects, tardive dyskinesia (TD), and use of antipsychotic medications at the study time were collected by a review of medical records in 2001, and by either a review of medical records or patient interview in both 2004 and 2009 using a questionnaire designed for the study. Only a review of medical records was used in some participating centers due to logistic reasons. The data were collected by the attending psychiatrist of the patient at the time of study or by members of the research team (experienced psychiatrists) with the agreement of the psychiatrist in charge of the patient. Doses of antipsychotic drugs were converted into chlorpromazine equivalent milligrams (CPZeq) [17 -19] . TD is treated separately from other forms of EPS because of its special characteristics and treatment strategy compared with other extrapyramidal symptoms. Consensus meetings on data collection and the uniformity of data entry were held before each survey. In REAP surveys, psychotropic drugs were categorized according to the World Health Organization Anatomic Therapeutic Chemical (WHO-ATC) system [20, 21] , and ACMs include trihexyphenidyl, biperiden, benztropine, promethazine, procyclidine, amantadine, piroheptine and mazaticol.
Statistical analysis
The data were analyzed using SPSS 13.0 for Windows. Comparisons among the 3 cohorts with respect to the proportion of individuals prescribed ACM in each study site were conducted using chi-square ( χ 2 ) tests. The comparisons between ACM and non-ACM groups with respect to socio-demographic and clinical characteristics were performed by independent samples t-test, Mann-Whitney U-test, and chi-square test, as appropriate. Multiple logistic regression analysis was used to determine the independent contribution of demographic and clinical variables to ACM use. The level of signifi cance was set at 0.05 (2-tailed).
Results ▼ • ▶ Table 2 compares the socio-demographic and clinical characteristics of the ACM and non-ACM groups for the whole sample.
• ▶ Table 3 shows the independent factors that were signifi cantly associated with ACM use. Patients taking ACM presented with more severe positive, negative symptoms and EPS. They were also more likely to receive fi rst-generation (FGAs) and depot antipsychotics and antipsychotic polypharmacy, and less likely to receive SGAs.
Discussion ▼
The results show that ACM use signifi cantly decreased in Asia between 2001 and 2009, but these drugs were still extensively prescribed for more than half of the patients in this region. This is basically in keeping with the fi ndings of previous studies of Asian schizophrenia inpatients. Chong et al. [22] found that 64 % of schizophrenia patients in long-stay wards in Singapore received ACM. Wu et al. [23] reported that 58.2 % of schizophrenia inpatients were on ACM in a major psychiatric hospital in China, while in Hong Kong the fi gures were 67.8 % and 61.8 % in 1996 and 1999, respectively. There could be several explanations for the high proportion of ACM prescriptions in this study. Asian patients have a lower threshold for the therapeutic and side eff ects of drugs compared with Caucasians [13, 24] , although this notion has been questioned [25] , leading to more ACM use for prophylaxis and treatment. Another factor could be the widely held belief in Asian societies that a combination of multiple drugs with diff erent pharmacological features is more eff ective [26] . Some clinicians are also concerned about the rebound phenomena and the subsequent deterioration in patients ' mental state following the cessation of ACM [27, 28] . Patients on ACM were very similar to patients without ACM in terms of age and dose of antipsychotics. Patients with severe positive and negative symptoms were more likely to be prescribed ACM. This association was expected because more severe symptoms usually necessitate higher antipsychotic doses and antipsychotic polypharmacy [34, 35] , and consequently an elevated risk of EPS. Prophylactic use of ACM is also more often considered in these severely ill patients. ACM are primarily prescribed for the prophylaxis and treatment of EPS. It was therefore expected that more patients with EPS would be on ACM. It has been documented that the continuous use of ACM may contribute to the development of TD [9, 36] , which explains why patients with TD were less likely to be prescribed ACM although the trend did not reach a signifi cant level (p = 0.052). Prescribing a combination of FGAs and ACM is common practice [23, 37 -39] , as was found in this study. As all depot antipsychotics in the REAP surveys were fi rst-generation drugs, patients on depot were more likely to have ACM. SGAs are less likely to induce EPS [40] , which explains their negative association with ACM in this study. The more frequent prescriptions of ACM to patients receiving antipsychotic polypharmacy (APP) could be accounted for by the attempt to prevent the anticipated EPS related to APP [1] . The strengths of this study are its large sample size and the number of participating study centers involved. The main limitations include the following. First, the generalizability of the results is limited because the study targeted only inpatients. Second, the severity of psychopathology and drug-induced side eff ects were not quantitatively assessed. Third, the conversion of diff erent antipsychotics into CPZeq is only a rough estimation, particularly for SGAs [38] . Finally, some important factors likely to infl uence ACM prescription, such as local prescription guidelines, type of psychiatric facilities (such as chronic vs . acute psychiatric hospitals) and reimbursement policies were not evaluated.
In conclusion, the results suggest that the prescription of ACM for schizophrenia inpatients in Asia has gradually decreased over recent years, but these drugs are still being prescribed for more than half of the inpatients with schizophrenia. Considering the increased use of SGAs and the fact that continuous administration of ACM often gives rise to distressing and disabling side eff ects, prescription of ACM should be further reduced.
It is important to emphasize the need to regularly monitor ACM prescriptions with particular attention to their unnecessary use for long-term prevention of EPS. Table 3 Factors associated with prescription of ACM in the whole sample by multiple logistic regression analysis with the non-ACM group as reference (n = 6 441).
P-value
Odds ratio 95 % C.I. 
